William A Wood1, Allison M Deal2, Antonia V Bennett3, Sandra A Mitchell4, Amy P Abernethy5, Ethan Basch3, Charlotte Bailey3, Bryce B Reeve6. 1. Lineberger Comprehensive Cancer Center, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Electronic address: wawood@med.unc.edu. 2. Biostatistics Core Facility, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 3. Lineberger Comprehensive Cancer Center, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 4. Outcomes Research Branch, Division of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, USA. 5. Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute, Durham, North Carolina, USA. 6. Lineberger Comprehensive Cancer Center, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Abstract
CONTEXT: Patient-reported outcomes (PROs) provide a way to understand the effects of hematopoietic cell transplantation (HCT)-related stress on patients' lives. We previously reported that weekly collection of PROs is feasible. OBJECTIVES: Here, we report on the feasibility of daily patient-reported symptom collection and examine the relationship between daily vs. weekly symptom reporting over time. METHODS: We analyzed data from 32 autologous and allogeneic HCT patients obtained until Day (D) +100. We used questions from the PRO version of the Common Terminology Criteria for Adverse Events to capture symptoms. RESULTS: We found that overall rates of daily survey completion were moderate to high (range 67%-86%). The effect size of the difference between the maximum daily severity score and the weekly severity score ranged from 0.15 to 0.35, and the concordance correlation coefficient ranged from 0.513 to 0.834. Concordance of daily and weekly surveys was higher for maximum daily severity rating and mean daily severity rating than for minimum daily severity rating or most recent daily severity rating. CONCLUSION: We conclude that a seven-day recall period for symptom severity provides acceptable accuracy and precision in the first 100 days after HCT. Further studies to explore the utility of daily symptom reporting within specific clinical contexts may be warranted.
CONTEXT: Patient-reported outcomes (PROs) provide a way to understand the effects of hematopoietic cell transplantation (HCT)-related stress on patients' lives. We previously reported that weekly collection of PROs is feasible. OBJECTIVES: Here, we report on the feasibility of daily patient-reported symptom collection and examine the relationship between daily vs. weekly symptom reporting over time. METHODS: We analyzed data from 32 autologous and allogeneic HCT patients obtained until Day (D) +100. We used questions from the PRO version of the Common Terminology Criteria for Adverse Events to capture symptoms. RESULTS: We found that overall rates of daily survey completion were moderate to high (range 67%-86%). The effect size of the difference between the maximum daily severity score and the weekly severity score ranged from 0.15 to 0.35, and the concordance correlation coefficient ranged from 0.513 to 0.834. Concordance of daily and weekly surveys was higher for maximum daily severity rating and mean daily severity rating than for minimum daily severity rating or most recent daily severity rating. CONCLUSION: We conclude that a seven-day recall period for symptom severity provides acceptable accuracy and precision in the first 100 days after HCT. Further studies to explore the utility of daily symptom reporting within specific clinical contexts may be warranted.
Authors: John R Wingard; I-Chan Huang; Kathleen A Sobocinski; Michael A Andrykowski; David Cella; J Douglas Rizzo; Marianne Brady; Mary M Horowitz; Michelle M Bishop Journal: Biol Blood Marrow Transplant Date: 2010-06-01 Impact factor: 5.742
Authors: Antonia V Bennett; Donald L Patrick; James F Lymp; Todd C Edwards; Christopher H Goss Journal: J Cyst Fibros Date: 2010-12 Impact factor: 5.482
Authors: Ethan M Basch; Bryce B Reeve; Sandra A Mitchell; Stephen B Clauser; Lori Minasian; Laura Sit; Ram Chilukuri; Paul Baumgartner; Lauren Rogak; Emily Blauel; Amy P Abernethy; Deborah Bruner Journal: Cancer J Date: 2011 Jul-Aug Impact factor: 3.360
Authors: William A Wood; Allison M Deal; Amy Abernethy; Ethan Basch; Claudio Battaglini; Yoon Hie Kim; Julia Whitley; Charlotte Shatten; Jon Serody; Thomas Shea; Bryce B Reeve Journal: Biol Blood Marrow Transplant Date: 2012-12-16 Impact factor: 5.742
Authors: Ethan Basch; Amy P Abernethy; C Daniel Mullins; Bryce B Reeve; Mary Lou Smith; Stephen Joel Coons; Jeff Sloan; Keith Wenzel; Cynthia Chauhan; Wayland Eppard; Elizabeth S Frank; Joseph Lipscomb; Stephen A Raymond; Merianne Spencer; Sean Tunis Journal: J Clin Oncol Date: 2012-10-15 Impact factor: 44.544
Authors: Tito R Mendoza; Amylou C Dueck; Antonia V Bennett; Sandra A Mitchell; Bryce B Reeve; Thomas M Atkinson; Yuelin Li; Kathleen M Castro; Andrea Denicoff; Lauren J Rogak; Richard L Piekarz; Charles S Cleeland; Jeff A Sloan; Deborah Schrag; Ethan Basch Journal: Clin Trials Date: 2017-03-20 Impact factor: 2.486
Authors: Kelly P McCarrier; Thomas M Atkinson; Kendra P A DeBusk; Astra M Liepa; Michael Scanlon; Stephen Joel Coons Journal: Clin Ther Date: 2016-04-01 Impact factor: 3.393